Our model also predicts that GTP-specific beta subunit of succinyl-CoA synthetase (SUCLG2) is selectively lethal in malignant prostate cancer cells because the alternative route via ATP-specific succinyl-CoA synthetase (SUCLA2) is absent in the malignant model (Fig. S2C). The gene discussed is SUCLA2; the disease is prostate carcinoma.